<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:47:43Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7745180" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7745180</identifier>
        <datestamp>2020-12-21</datestamp>
        <setSpec>phenejm</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">N Engl J Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">N Engl J Med</journal-id>
              <journal-id journal-id-type="publisher-id">nejm</journal-id>
              <journal-title-group>
                <journal-title>The New England Journal of Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0028-4793</issn>
              <issn pub-type="epub">1533-4406</issn>
              <publisher>
                <publisher-name>Massachusetts Medical Society</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7745180</article-id>
              <article-id pub-id-type="pmcid">PMC7745180</article-id>
              <article-id pub-id-type="pmc-uid">7745180</article-id>
              <article-id pub-id-type="pmid">33306283</article-id>
              <article-id pub-id-type="pmid">33306283</article-id>
              <article-id pub-id-type="doi">10.1056/NEJMoa2031994</article-id>
              <article-id pub-id-type="publisher-id">NJ202012110000001</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Original Article</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" specific-use="authenticated" authenticated="false">http://orcid.org/0000-0002-6489-6294</contrib-id>
                  <name>
                    <surname>Kalil</surname>
                    <given-names>Andre C.</given-names>
                  </name>
                  <degrees>M.D., M.P.H.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Patterson</surname>
                    <given-names>Thomas F.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mehta</surname>
                    <given-names>Aneesh K.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tomashek</surname>
                    <given-names>Kay M.</given-names>
                  </name>
                  <degrees>M.D., M.P.H.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wolfe</surname>
                    <given-names>Cameron R.</given-names>
                  </name>
                  <degrees>M.B., B.S., M.P.H.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ghazaryan</surname>
                    <given-names>Varduhi</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Marconi</surname>
                    <given-names>Vincent C.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ruiz-Palacios</surname>
                    <given-names>Guillermo M.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hsieh</surname>
                    <given-names>Lanny</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kline</surname>
                    <given-names>Susan</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tapson</surname>
                    <given-names>Victor</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Iovine</surname>
                    <given-names>Nicole M.</given-names>
                  </name>
                  <degrees>M.D., Ph.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jain</surname>
                    <given-names>Mamta K.</given-names>
                  </name>
                  <degrees>M.D., M.P.H.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sweeney</surname>
                    <given-names>Daniel A.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>El Sahly</surname>
                    <given-names>Hana M.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Branche</surname>
                    <given-names>Angela R.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Regalado Pineda</surname>
                    <given-names>Justino</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lye</surname>
                    <given-names>David C.</given-names>
                  </name>
                  <degrees>M.B., B.S.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sandkovsky</surname>
                    <given-names>Uriel</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Luetkemeyer</surname>
                    <given-names>Anne F.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cohen</surname>
                    <given-names>Stuart H.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Finberg</surname>
                    <given-names>Robert W.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Jackson</surname>
                    <given-names>Patrick E.H.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Taiwo</surname>
                    <given-names>Babafemi</given-names>
                  </name>
                  <degrees>M.B., B.S.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Paules</surname>
                    <given-names>Catherine I.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Arguinchona</surname>
                    <given-names>Henry</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Goepfert</surname>
                    <given-names>Paul</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ahuja</surname>
                    <given-names>Neera</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Frank</surname>
                    <given-names>Maria</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" specific-use="authenticated" authenticated="false">http://orcid.org/0000-0002-2344-7695</contrib-id>
                  <name>
                    <surname>Oh</surname>
                    <given-names>Myoung-don</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kim</surname>
                    <given-names>Eu S.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" specific-use="authenticated" authenticated="false">http://orcid.org/0000-0001-7870-2879</contrib-id>
                  <name>
                    <surname>Tan</surname>
                    <given-names>Seow Y.</given-names>
                  </name>
                  <degrees>M.B., B.S.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mularski</surname>
                    <given-names>Richard A.</given-names>
                  </name>
                  <degrees>M.D., M.S.H.S.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nielsen</surname>
                    <given-names>Henrik</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ponce</surname>
                    <given-names>Philip O.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Taylor</surname>
                    <given-names>Barbara S.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Larson</surname>
                    <given-names>LuAnn</given-names>
                  </name>
                  <degrees>R.N., B.S.N.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rouphael</surname>
                    <given-names>Nadine G.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Saklawi</surname>
                    <given-names>Youssef</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cantos</surname>
                    <given-names>Valeria D.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ko</surname>
                    <given-names>Emily R.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Engemann</surname>
                    <given-names>John J.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Amin</surname>
                    <given-names>Alpesh N.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Watanabe</surname>
                    <given-names>Miki</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Billings</surname>
                    <given-names>Joanne</given-names>
                  </name>
                  <degrees>M.D., M.P.H.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Elie</surname>
                    <given-names>Marie-Carmelle</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Davey</surname>
                    <given-names>Richard T.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Burgess</surname>
                    <given-names>Timothy H.</given-names>
                  </name>
                  <degrees>M.D., M.P.H.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ferreira</surname>
                    <given-names>Jennifer</given-names>
                  </name>
                  <degrees>Sc.M.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Green</surname>
                    <given-names>Michelle</given-names>
                  </name>
                  <degrees>M.P.H.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Makowski</surname>
                    <given-names>Mat</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cardoso</surname>
                    <given-names>Anabela</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>de Bono</surname>
                    <given-names>Stephanie</given-names>
                  </name>
                  <degrees>M.D., Ph.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Bonnett</surname>
                    <given-names>Tyler</given-names>
                  </name>
                  <degrees>M.S.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Proschan</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Deye</surname>
                    <given-names>Gregory A.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dempsey</surname>
                    <given-names>Walla</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nayak</surname>
                    <given-names>Seema U.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Dodd</surname>
                    <given-names>Lori E.</given-names>
                  </name>
                  <degrees>Ph.D.</degrees>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" specific-use="authenticated" authenticated="false">http://orcid.org/0000-0002-4879-4941</contrib-id>
                  <name>
                    <surname>Beigel</surname>
                    <given-names>John H.</given-names>
                  </name>
                  <degrees>M.D.</degrees>
                </contrib>
                <aff>From the University of Nebraska Medical Center, Omaha (A.C.K., L.L.); University of Texas Health San Antonio, University Health, and the South Texas Veterans Health Care System, San Antonio (T.F.P., P.O.P., B.S.T.), UT Southwestern Medical Center, Parkland Health and Hospital System (M.K.J.) and Baylor Scott and White Health (U.S.), Dallas, and Baylor College of Medicine, Houston (H.M.E.S.) — all in Texas; Emory University (A.K.M., N.G.R., Y.S., V.C.M.) and Grady Memorial Hospital (V.D.C.), Atlanta, and Atlanta Veterans Affairs Medical Center, Decatur (V.C.M.) — both in Georgia; the National Institute of Allergy and Infectious Diseases, National Institutes of Health (K.M.T., V.G., R.T.D., M.P., G.A.D., W.D., S.U.N., L.E.D., J.H.B.), and the Infectious Disease Clinical Research Program, Uniformed Services University of the Health Sciences (T.H.B.), Bethesda, and Emmes (J.F., M.G., M.M.) and Clinical Monitoring Research Program Directorate, Frederick National Laboratory (T.B.), Rockville — both in Maryland; Duke University, Durham, NC (C.R.W., E.R.K., J.J.E.); Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, (G.M.R.-P.) and Instituto Nacional de Enfermedades Respiratorias (J.R.P.), Mexico City; University of California Irvine, Irvine (L.H., A.N.A., M.W.), Cedars–Sinai Medical Center, Los Angeles (V.T.), University of California, San Diego, La Jolla (D.A.S.), University of California, San Francisco, San Francisco (A.F.L.), University of California, Davis, Davis (S.H.C.), and Stanford University, Stanford (N.A.) — all in California; University of Minnesota Medical School, Minneapolis (S.K., J.B.); University of Florida, Gainesville (N.M.I., M.-C.E.); University of Rochester, Rochester, NY (A.R.B.); National Center for Infectious Diseases, Tan Tock Seng Hospital, Lee Kong Chian School of Medicine, and Yong Loo Lin School of Medicine (D.C.L.), and Changi General Hospital (S.Y.T.), Singapore; University of Massachusetts Medical School, Worcester (R.W.F.); University of Virginia, Charlottesville (P.E.H.J.); Northwestern University, Chicago (B.T.); Penn State Health Milton S. Hershey Medical Center, Hershey, PA (C.I.P.); Providence Sacred Heart Medical Center, Spokane, WA (H.A.); University of Alabama at Birmingham, Birmingham (P.G.); Denver Health and Hospital Authority, Denver (M.F.); Seoul National University Hospital, Seoul (M.O.), and Seoul National University Bundang Hospital, Seongnam (E.S.K.) — both in South Korea; Kaiser Permanente Northwest, Portland, OR (R.A.M.); Aalborg University Hospital, Aalborg, Denmark (H.N.); and Eli Lilly, Indianapolis (A.C., S.B.).</aff>
              </contrib-group>
              <author-notes>
                <corresp>Address reprint requests to Dr. Kalil at the University of Nebraska Medical Center, 985400 Nebraska Medicine, Omaha, NE 68198-5400, or at <email xlink:href="akalil@unmc.edu">akalil@unmc.edu</email>.</corresp>
                <fn fn-type="study-group-members" id="fn1">
                  <p>A complete list of members of the ACTT-2 Study Group is provided in the <xref rid="ap2" ref-type="app">Supplementary Appendix</xref>, available at NEJM.org.</p>
                </fn>
              </author-notes>
              <pub-date iso-8601-date="2020-12-11T12:00:00-05:00" pub-type="epub">
                <day>11</day>
                <month>12</month>
                <year>2020</year>
              </pub-date>
              <elocation-id>NEJMoa2031994</elocation-id>
              <permissions>
                <copyright-statement>Copyright © 2020 Massachusetts Medical Society. All rights reserved.</copyright-statement>
                <copyright-year>2020</copyright-year>
                <copyright-holder>Massachusetts Medical Society</copyright-holder>
                <license>
                  <ali:license_ref specific-use="version-of-record">http://www.nejmgroup.org/legal/terms-of-use.htm</ali:license_ref>
                </license>
                <license>
                  <license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use, except commercial resale, and analyses in any form or by any means with acknowledgment of the original source. PMC is granted a license to make this article available via PMC and Europe PMC, subject to existing copyright protections.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="NEJMoa2031994.pdf"/>
              <abstract abstract-type="summary">
                <title>Abstract</title>
                <sec id="sc_a1">
                  <title>Background</title>
                  <p>Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known.</p>
                </sec>
                <sec id="sc_a2">
                  <title>Methods</title>
                  <p>We conducted a double-blind, randomized, placebo-controlled trial evaluating baricitinib plus remdesivir in hospitalized adults with Covid-19. All the patients received remdesivir (≤10 days) and either baricitinib (≤14 days) or placebo (control). The primary outcome was the time to recovery. The key secondary outcome was clinical status at day 15.</p>
                </sec>
                <sec id="sc_a3">
                  <title>Results</title>
                  <p>A total of 1033 patients underwent randomization (with 515 assigned to combination treatment and 518 to control). Patients receiving baricitinib had a median time to recovery of 7 days (95% confidence interval [CI], 6 to 8), as compared with 8 days (95% CI, 7 to 9) with control (rate ratio for recovery, 1.16; 95% CI, 1.01 to 1.32; P=0.03), and a 30% higher odds of improvement in clinical status at day 15 (odds ratio, 1.3; 95% CI, 1.0 to 1.6). Patients receiving high-flow oxygen or noninvasive ventilation at enrollment had a time to recovery of 10 days with combination treatment and 18 days with control (rate ratio for recovery, 1.51; 95% CI, 1.10 to 2.08). The 28-day mortality was 5.1% in the combination group and 7.8% in the control group (hazard ratio for death, 0.65; 95% CI, 0.39 to 1.09). Serious adverse events were less frequent in the combination group than in the control group (16.0% vs. 21.0%; difference, −5.0 percentage points; 95% CI, −9.8 to −0.3; P=0.03), as were new infections (5.9% vs. 11.2%; difference, −5.3 percentage points; 95% CI, −8.7 to −1.9; P=0.003).</p>
                </sec>
                <sec id="sc_a4">
                  <title>Conclusions</title>
                  <p>Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov number, <ext-link xlink:href="http://clinicaltrials.gov/show/NCT04401579" ext-link-type="uri">NCT04401579</ext-link>.)</p>
                </sec>
              </abstract>
              <kwd-group kwd-group-type="nejm-topics">
                <nested-kwd>
                  <compound-kwd>
                    <compound-kwd-part content-type="code">12</compound-kwd-part>
                    <compound-kwd-part content-type="keyword">Pulmonary/Critical Care</compound-kwd-part>
                  </compound-kwd>
                  <nested-kwd>
                    <compound-kwd>
                      <compound-kwd-part content-type="code">12_1</compound-kwd-part>
                      <compound-kwd-part content-type="keyword">Pulmonary/Critical Care General</compound-kwd-part>
                    </compound-kwd>
                  </nested-kwd>
                </nested-kwd>
                <nested-kwd>
                  <compound-kwd>
                    <compound-kwd-part content-type="code">18</compound-kwd-part>
                    <compound-kwd-part content-type="keyword">Infectious Disease</compound-kwd-part>
                  </compound-kwd>
                  <nested-kwd>
                    <compound-kwd>
                      <compound-kwd-part content-type="code">18_6</compound-kwd-part>
                      <compound-kwd-part content-type="keyword">Viral Infections</compound-kwd-part>
                    </compound-kwd>
                  </nested-kwd>
                </nested-kwd>
              </kwd-group>
              <funding-group specific-use="FundRef">
                <award-group>
                  <funding-source id="funder1">
                    <institution-wrap>
                      <institution>National Institute of Allergy and Infectious Diseases</institution>
                      <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>NCT04401579</award-id>
                </award-group>
              </funding-group>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>release-date-display-string</meta-name>
                  <meta-value>2020-12-11T12:00:00-05:00</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>release-date-year</meta-name>
                  <meta-value>2020</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>release-date-month</meta-name>
                  <meta-value>12</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>release-date-day</meta-name>
                  <meta-value>11</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>release-date-hour</meta-name>
                  <meta-value>12</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>release-date-minute</meta-name>
                  <meta-value>00</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>release-date-second</meta-name>
                  <meta-value>00</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>release-date-time-zone</meta-name>
                  <meta-value>-05:00</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <p>In May 2020, the first stage of the Adaptive Covid-19 Treatment Trial (ACTT-1), a randomized, double-blind, placebo-controlled trial, showed that remdesivir is an effective treatment for hospitalized adult patients with coronavirus disease 2019 (Covid-19) pneumonia.<sup><xref rid="r1" ref-type="bibr">1</xref></sup> Despite the benefits of remdesivir, substantial morbidity and mortality due to Covid-19 remain. Emerging data suggest that disease severity may be due in part to a dysregulated inflammatory response.<sup><xref rid="r2" ref-type="bibr">2</xref></sup> It is postulated that mitigating the immune response and preventing a hyperinflammatory state may further improve clinical outcomes. Baricitinib, an orally administered, selective inhibitor of Janus kinase (JAK) 1 and 2, was predicted with the use of artificial intelligence algorithms to be a potential therapeutic against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r4" ref-type="bibr">4</xref></sup> Baricitinib inhibits the intracellular signaling pathway of cytokines known to be elevated in severe Covid-19, including interleukin-2, interleukin-6, interleukin-10, interferon-γ, and granulocyte–macrophage colony-stimulating factor; acts against SARS-CoV-2 through the impairment of AP2-associated protein kinase 1 and the prevention of SARS-CoV-2 cellular entry and infectivity; and improves lymphocyte counts in patients with Covid-19.<sup><xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r5" ref-type="bibr">5-8</xref></sup> In three case series of patients with Covid-19, baricitinib treatment was associated with both an improvement in oxygenation and a reduction in select inflammatory markers.<sup><xref rid="r9" ref-type="bibr">9-11</xref></sup> Randomized, controlled trials are needed to further understand the role of immunomodulation in patients with Covid-19.<sup><xref rid="r12" ref-type="bibr">12</xref></sup> After the successful completion of ACTT-1, we designed the next iteration of ACTT (ACTT-2) to evaluate whether the combination of baricitinib plus remdesivir was superior to remdesivir alone.</p>
            <sec sec-type="methods" id="sc1">
              <title>Methods</title>
              <sec id="sc1.1">
                <title>Design</title>
                <p>The ACTT-2 protocol was designed and written by a working group of the ACTT investigators and the sponsor (the National Institute of Allergy and Infectious Diseases), with input from the manufacturer of baricitinib, Eli Lilly. Investigators and staff at participating sites gathered the data, which were then analyzed by statisticians at the statistical and data center (Emmes) and the sponsor. The authors wrote the manuscript, and, on behalf of the ACTT-2 Study Group, vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol.</p>
                <p>Enrollment into this double-blind, placebo-controlled trial began on May 8, 2020, and ended on July 1, 2020. There were 67 trial sites in 8 countries: the United States (55 sites), Singapore (4), South Korea (2), Mexico (2), Japan (1), Spain (1), the United Kingdom (1), and Denmark (1). Eligible patients were randomly assigned in a 1:1 ratio to receive either remdesivir and baricitinib or remdesivir and placebo. Randomization was stratified according to trial site and disease severity at enrollment (see the <xref rid="ap2" ref-type="app">Supplementary Appendix</xref>, available with the full text of this article at NEJM.org). Patients received remdesivir intravenously as a 200-mg loading dose on day 1, followed by a 100-mg maintenance dose administered daily on days 2 through 10 or until hospital discharge or death. Baricitinib was administered as a 4-mg daily dose (either orally [two 2-mg tablets] or through a nasogastric tube) for 14 days or until hospital discharge. Patients with an estimated glomerular filtration rate of less than 60 ml per minute received baricitinib at a dose of 2 mg once daily. A matching oral placebo was administered according to the same schedule as the active drug. All the patients received standard supportive care at the trial site hospital. Venous thromboembolism prophylaxis was recommended for all the patients without a major contraindication. If a hospital had a written policy for Covid-19 treatments, patients could receive those treatments. In the absence of a written policy, other experimental treatment and off-label use of marketed medications intended as specific treatment for Covid-19 were prohibited. This included glucocorticoids, which were permitted only for standard indications such as adrenal insufficiency, asthma exacerbation, laryngeal edema, septic shock, and acute respiratory distress syndrome.</p>
                <p>The trial protocol was approved by the institutional review board at each site (or a centralized institutional review board as applicable) and was overseen by an independent data and safety monitoring board. Written informed consent was obtained from each patient or from the patient’s legally authorized representative if the patient was unable to provide consent. Full details of the trial design, conduct, oversight, and analyses are provided in the <xref rid="ap1" ref-type="app">protocol</xref> and statistical analysis plan (available at NEJM.org).</p>
              </sec>
              <sec id="sc1.2">
                <title>Procedures</title>
                <p>All patients were evaluated daily during their hospitalization, from day 1 through day 29. (See the full description of procedures in the <xref rid="ap2" ref-type="app">Supplementary Appendix</xref>.) The trial team was unaware of the trial-group assignments until after all data queries were resolved and the database was locked. The first draft of the manuscript was written by the first author, and then all the authors contributed to the subsequent versions. No one who is not an author contributed to the writing of the manuscript.</p>
              </sec>
              <sec id="sc1.3">
                <title>Outcomes and Statistical Analysis</title>
                <p>The primary outcome measure was the time to recovery, with the day of recovery defined as the first day, during the 28 days after enrollment, on which a patient attained category 1, 2, or 3 on the eight-category ordinal scale. The competing event of death was handled in a manner similar to the Fine–Gray competing-risk approach.<sup><xref rid="r13" ref-type="bibr">13</xref></sup> The categories are the same as those used in ACTT-1<sup><xref rid="r1" ref-type="bibr">1</xref></sup> and are listed in Table S1 in the <xref rid="ap2" ref-type="app">Supplementary Appendix</xref>. The primary analysis was a stratified log-rank test of the time to recovery with remdesivir plus baricitinib as compared with remdesivir plus placebo, stratified according to baseline disease severity (i.e., score on the ordinal scale of 4 or 5 vs. 6 or 7 at enrollment).</p>
                <p>The key secondary outcome measure was clinical status at day 15, based on the eight-category ordinal scale. Other secondary outcome measures included the time to improvement by one or two categories from the ordinal score at baseline; clinical status, as assessed on the ordinal scale at days 3, 5, 8, 11, 15, 22, and 29; mean change in the ordinal score from day 1 to days 3, 5, 8, 11, 15, 22, and 29; time to discharge or to a National Early Warning Score of 2 or less (on a scale from 0 to 20, with higher scores indicating greater clinical risk) that was maintained for 24 hours, whichever occurred first; change in the National Early Warning Score from day 1 to days 3, 5, 8, 11, 15, 22, and 29; number of days of receipt of supplemental oxygen, noninvasive ventilation or high-flow oxygen, and invasive ventilation or extracorporeal membrane oxygenation (ECMO) up to day 29 (if these were being used at baseline); the incidence and duration of new use of oxygen, new use of noninvasive ventilation or high-flow oxygen, and new use of invasive ventilation or ECMO; duration of hospitalization up to day 29 (patients who remained hospitalized at day 29 had a value of 28 days); and mortality at 14 and 28 days after enrollment. Secondary safety outcomes included grade 3 and 4 adverse events and serious adverse events that occurred through day 29, discontinuation or temporary suspension of trial-product administration for any reason, and changes in assessed laboratory values over time. There was a single primary hypothesis test. For secondary outcomes, no adjustments for multiplicity were made.</p>
                <p>Prespecified subgroups were defined according to sex, disease severity (as defined for stratification and by an ordinal score of 4, 5, 6, and 7 at enrollment), age (18 to 39 years, 40 to 64 years, or ≥65 years), race, ethnic group, duration of symptoms before randomization (measured as ≤10 days or &gt;10 days, in quartiles, and as the median), site location, and presence of coexisting conditions.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="sc2">
              <title>Results</title>
              <sec id="sc2.1">
                <title>Patients</title>
                <p>Of 1067 patients assessed for eligibility, 1033 underwent randomization; 515 were assigned to the combination group, and 518 to the control group (<xref rid="f1" ref-type="fig">Figure 1</xref>). The intention-to-treat population included 706 patients with moderate disease (ordinal score of 4 or 5 [not receiving ventilation]) and 327 with severe disease (ordinal score of 6 or 7 [receiving noninvasive or invasive ventilation]). Of those assigned to the combination group, 507 (98.4%) received treatment as assigned. Of those assigned to the control group, 509 (98.3%) received treatment as assigned. A total of 498 patients in the combination group and 495 in the control group completed the trial through day 29, recovered, or died. The mean age of the patients was 55.4 years, and 63.1% were male (<xref rid="t1" ref-type="table">Table 1</xref>). Overall, 48.0% of the patients were White, 15.1% were Black, 9.8% were Asian, and 1.0% were American Indian or Alaska Native; 51.4% were Hispanic or Latino (<xref rid="t1" ref-type="table">Table 1</xref>). The characteristics of the U.S. patients are shown in Table S4.</p>
              </sec>
              <sec id="sc2.2">
                <title>Primary Outcome</title>
                <p>Patients who received combination treatment with baricitinib plus remdesivir recovered a median of 1 day faster than patients who received remdesivir and placebo (median, 7 days vs. 8 days; rate ratio for recovery, 1.16; 95% confidence interval [CI], 1.01 to 1.32; P=0.03 by log-rank test stratified according to actual baseline severity) (<xref rid="f2" ref-type="fig">Figure 2</xref> and <xref rid="t2" ref-type="table">Table 2</xref>). When analyzed according to the severity entered at the time of randomization (moderate vs. severe), the hazard ratio was 1.15 (95% CI, 1.00 to 1.31; P=0.047) (Table S6). The median time to recovery among patients receiving noninvasive ventilation or high-flow oxygen (baseline ordinal score of 6) was 10 days in the combination group and 18 days in the control group (rate ratio for recovery, 1.51; 95% CI, 1.10 to 2.08). Among patients with a baseline score of 4 (no oxygen) and 5 (supplemental oxygen), the rate ratio for recovery was 0.88 (95% CI, 0.63 to 1.23) and 1.17 (95% CI, 0.98 to 1.39), respectively. For those receiving mechanical ventilation or ECMO at enrollment (baseline ordinal score of 7), the rate ratio for recovery was 1.08 (95% CI, 0.59 to 1.97) (<xref rid="t2" ref-type="table">Table 2</xref> and <xref rid="f3" ref-type="fig">Figure 3</xref>). The rate ratio for recovery among the 223 patients who received glucocorticoids for clinical indications during the trial was 1.06 (95% CI, 0.75 to 1.48). A sensitivity analysis with a random effect for hospital site yielded similar results (conditional random-effects estimate of rate ratio for recovery, 1.16; 95% CI, 1.01 to 1.33; restricted maximum likelihood–based random-effects estimate of variance, 0.0305) (Table S13).</p>
              </sec>
              <sec id="sc2.3">
                <title>Key Secondary Outcome</title>
                <p>The odds of improvement in clinical status at day 15 as assessed with the ordinal scale were greater in the combination group than in the control group (odds ratio for improvement, 1.3; 95% CI, 1.0 to 1.6). Patients with a baseline ordinal score of 6 who received combination treatment were most likely to have clinical improvement at day 15 (odds ratio, 2.2; 95% CI, 1.4 to 3.6) (<xref rid="t2" ref-type="table">Table 2</xref> and Fig. S1).</p>
              </sec>
              <sec id="sc2.4">
                <title>Mortality</title>
                <p>The Kaplan–Meier estimates of mortality at day 28 after randomization were 5.1% (95% CI, 3.5 to 7.6) in the combination group and 7.8% (95% CI, 5.7 to 10.6) in the control group (hazard ratio for death, 0.65; 95% CI, 0.39 to 1.09). The greatest numerical differences in mortality between patients in the combination group and those in the control group were observed among those with a baseline ordinal score of 5 (1.9% vs. 4.7%; hazard ratio, 0.40; 95% CI, 0.14 to 1.14) or 6 (7.5% vs. 12.9%; hazard ratio, 0.55; 95% CI, 0.22 to 1.38). The Kaplan–Meier estimates of mortality at 14 days after randomization were 1.6% in the combination group and 3.0% in the control group (hazard ratio, 0.54; 95% CI, 0.23 to 1.28) (<xref rid="t2" ref-type="table">Table 2</xref> and Fig. S2).</p>
              </sec>
              <sec id="sc2.5">
                <title>Additional Secondary Outcomes</title>
                <p>The median time to an improvement by one category on the ordinal scale was 6 days in the combination group and 8 days in the control group (rate ratio, 1.21; 95% CI, 1.06 to 1.39), and the median time to discharge or a National Early Warning Score of 2 or less for 24 hours was 6 days and 7 days in the respective groups (rate ratio, 1.24; 95% CI, 1.07 to 1.44) (<xref rid="t3" ref-type="table">Table 3</xref>). The incidence of new use of oxygen was lower in the combination group than in the control group (22.9% vs. 40.3%; difference, −17.4 percentage points; 95% CI, −31.6 to −2.1), as was the incidence of new use of mechanical ventilation or ECMO (10.0% vs. 15.2%; difference, −5.2 percentage points; 95% CI, −9.5 to −0.9). The median number of days of receipt of mechanical ventilation or ECMO among the 128 patients in whom these interventions were started after enrollment or who died with no observed new use was 16 days in the combination group and 27 days in the control group (difference, −11.0; 95% CI, −18.3 to −3.7). The incidence of progression to death or noninvasive or invasive ventilation was lower in the combination group than in the control group (22.5% vs. 28.4%; rate ratio, 0.77; 95% CI, 0.60 to 0.98), as was the incidence of progression to death or invasive ventilation (12.2% vs. 17.2%; rate ratio, 0.69; 95% CI, 0.50 to 0.95).</p>
              </sec>
              <sec id="sc2.6">
                <title>Safety Outcomes</title>
                <p>Grade 3 or 4 adverse events occurred in 207 patients (40.7%) in the combination group and 238 (46.8%) in the control group (Table S11). A total of 25 grade 3 or 4 adverse events were judged by the principal investigators to be related to combination treatment and 28 to control (Table S10). The most common grade 3 or 4 adverse events occurring in at least 5% of all patients were hyperglycemia, anemia, decreased lymphocyte count, and acute kidney injury (Table S10). The incidence of these adverse events was similar in the two treatment groups. The percentage of patients who were reported to have a serious or nonserious adverse event of venous thromboembolism was similar in the combination group and the control group (21 patients [4.1%] and 16 patients [3.1%], respectively; difference, 1.0 percentage points; 95% CI, −1.3 to 3.3).</p>
                <p>Serious adverse events occurred in 81 patients (16.0%) in the combination group, and six of these events were thought to be related to the trial product (Table S7). Serious adverse events occurred in 107 patients (21.0%) in the control group, and five of these events were thought to be related to the trial product. The between-group difference was −5.0 percentage points (95% CI, −9.8 to −0.3; P = 0.03). The incidences of all serious adverse events, all adverse events, serious adverse events with fatal outcome, and adverse events leading to discontinuation of the trial product were each lower in the combination group than in the control group. Overall, the incidence of serious or nonserious adverse events of new infection was lower in the combination group (30 patients [5.9%]) than in the control group (57 patients [11.2%]) (difference, −5.3 percentage points; 95% CI, −8.7 to −1.9; P=0.003). Patients who received glucocorticoids after randomization had a higher incidence of serious or nonserious new infection than those who did not (56 of 223 patients [25.1%] vs. 44 of 793 patients [5.5%]).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="sc3">
              <title>Discussion</title>
              <p>The results of this randomized, double-blind, placebo-controlled trial show that combination treatment with the antiinflammatory drug baricitinib and the antiviral drug remdesivir was safe and superior to remdesivir alone for the treatment of hospitalized patients with Covid-19 pneumonia. The beneficial effects of the combination treatment were seen both in the primary outcome, with a 1-day shorter time to recovery, and in the key secondary outcome, with a greater improvement in clinical status as assessed on the ordinal scale. Although ACTT-2 was not powered to detect a difference in mortality between the two groups, both the survival rate and the time-to-death analyses favored combination treatment. These clinical benefits were observed across different age groups, sexes, ethnic groups, and races and were independent of symptom duration or disease severity at enrollment. The large proportion of Hispanic or Latino patients who were enrolled in the trial reflects the disproportionate effect of the pandemic on racial and ethnic minorities with respect to high incidences of hospitalization.<sup><xref rid="r14" ref-type="bibr">14</xref></sup></p>
              <p>The observed benefit of combination treatment was most evident in patients with a baseline ordinal score of 5 (supplemental oxygen) or 6 (high-flow oxygen or noninvasive ventilation), among whom the median time to recovery was, respectively, 1 and 8 days sooner with combination treatment than with placebo. Patients with a baseline ordinal score of 6 who received combination treatment were twice as likely as those in the control group to have improved clinical status at day 15 (odds ratio, 2.2; 95% CI, 1.4 to 3.6). The faster recovery in patients who received baricitinib plus remdesivir suggests that the combination treatment may have an effect in lowering the hospital-associated risk of nosocomial infections, thrombosis, and errors in hospital drug administration. Moreover, faster recovery also decreases the burden on the health care system, potentially increasing capacity, which is of critical importance during a surge of cases.</p>
              <p>In addition, the combination treatment showed clinical benefits directly relevant to patient care, such as a difference of −17.4 percentage points in new use of oxygen (22.9% vs. 40.3%) and a difference of −5.2 percentage points in new use of mechanical ventilation or ECMO (10.0% vs. 15.2%). In fact, the odds of progression to death or invasive ventilation were 31% lower in the combination group than in the control group (hazard ratio, 0.69; 95% CI, 0.50 to 0.95), and patients in the combination group had 11 fewer days receiving new mechanical ventilation than those in the control group.</p>
              <p>Despite concerns about immunosuppression, secondary infections, and thrombosis with use of JAK inhibitors, the addition of baricitinib was not associated with a significantly higher incidence of adverse events or thromboembolic events. In fact, patients receiving baricitinib plus remdesivir had a significantly lower incidence of adverse events, adverse events leading to discontinuation of the trial drug, serious adverse events, serious adverse events with a fatal outcome, and infection-related adverse events than patients who received remdesivir alone. The consistently lower incidence of adverse events with baricitinib may be related to its action in reducing inflammatory-mediated lung injury and improving lymphocyte counts, its antiviral properties, or its associated shorter recovery time and faster clinical improvement, all of which could have reduced the risk of nosocomial infection. Another ongoing trial may provide more information regarding the effects of baricitinib (ClinicalTrials.gov number, <ext-link xlink:href="http://clinicaltrials.gov/show/NCT04421027" ext-link-type="uri">NCT04421027</ext-link>). In summary, our results and the characteristics of baricitinib, including the fact that it is an oral drug with few drug–drug interactions and a good safety profile, lend itself to use in low-to-middle-income countries.</p>
              <p>The Randomized Evaluation of Covid-19 Therapy (RECOVERY) trial evaluated dexamethasone in patients with Covid-19<sup><xref rid="r15" ref-type="bibr">15</xref></sup> and showed a significant benefit in survival, most pronounced in patients receiving mechanical ventilation, and a 1-day shorter hospital stay. Baricitinib and dexamethasone have important biologic differences, and ACTT-2 and the RECOVERY trial have design differences. Dexamethasone has a long half-life, acts on glucocorticoid receptors, and reduces inflammation through a broad-pathway approach that has been associated with immunosuppression, hospital-acquired infections, gastrointestinal bleeding, hyperglycemia, and neuromuscular weakness, even with short courses.<sup><xref rid="r16" ref-type="bibr">16</xref></sup> Baricitinib has a short half-life, acts on targeted critical pathways to reduce inflammation while minimizing biologic redundancy with less immunosuppression, and may have antiviral activity.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> The two trials had different designs and cannot be compared directly. The high mortality in the control group of the RECOVERY trial and the low mortality in the control group of ACTT-2 suggest that these trials might not be generalizable to the same patient population. Only a randomized, double-blind, placebo-controlled, head-to-head comparison of baricitinib plus remdesivir with dexamethasone plus remdesivir will allow the efficacy and safety differences between these two approaches to be fully understood.</p>
              <p>Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status, notably among patients receiving high-flow oxygen or noninvasive mechanical ventilation. The combination was associated with fewer serious adverse events.</p>
            </sec>
          </body>
          <back>
            <ack>
              <p>We thank the members of the ACTT-2 Study Team (see the <xref rid="ap2" ref-type="app">Supplementary Appendix</xref>) for their many contributions in conducting the trial, the members of the data and safety monitoring board (Michael G. Ison, M.D. [chair], Northwestern University Feinberg School of Medicine; Nina Singh, M.D., University of Pittsburgh; Bernd Salzberger, M.D., Ph.D., University of Regensburg; Wendy Leisenring, Sc.D., Fred Hutchinson Cancer Research Center; Peter Sasieni, Ph.D., King’s College London; and Kelvin Kai-Wang To, M.B., B.S., M.D., University of Hong Kong) for their oversight, and the patients for their altruism in participating in this trial.</p>
            </ack>
            <fn-group>
              <fn fn-type="supported-by">
                <p>The trial was sponsored and primarily funded by the <named-content content-type="funder" rid="funder1">NIAID</named-content>, National Institutes of Health (NIH), Bethesda, MD. This trial has been funded in part with federal funds from the <named-content content-type="funder" rid="funder1">NIAID</named-content> and the National Cancer Institute, NIH, under contract HHSN261200800001E 75N910D00024, task order number 75N91019F00130/75N91020F00010, and by the Department of Defense, Defense Health Program. This trial has been supported in part by the <named-content content-type="funder" rid="funder1">NIAID</named-content> of the NIH under award numbers UM1AI148684, UM1AI148576, UM1AI148573, UM1AI148575, UM1AI148452, UM1AI148685, UM1AI148450, and UM1AI148689 and by NIH Stimulating Access to Research in Residency grant 5R38AI140299-02. The trial has also been funded in part by the governments of Japan, Mexico, Denmark, and Singapore. The trial site in South Korea received funding from the Seoul National University Hospital. Support for the London International Coordinating Centre was also provided by the United Kingdom Medical Research Council (MRC_UU_12023/23).</p>
              </fn>
              <fn fn-type="financial-disclosure">
                <p><xref rid="ap3" ref-type="app">Disclosure forms</xref> provided by the authors are available with the full text of this article at NEJM.org.</p>
              </fn>
            </fn-group>
            <notes>
              <p content-type="disclaimer">The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, the Uniformed Services University of the Health Sciences, the Henry M. Jackson Foundation for the Advancement of Military Medicine, the Departments of the Army, Navy, or Air Force, the Department of Defense, or the Department of Veterans Affairs, nor does any mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Gilead Sciences provided remdesivir for use in this trial but did not provide any financial support. Eli Lilly provided baricitinib for use in this trial but did not provide any financial support. Employees of Gilead Sciences and Eli Lilly participated in discussions about protocol development and in weekly protocol team calls. The National Institute of Allergy and Infectious Diseases (NIAID) ultimately made all decisions regarding trial design and implementation.</p>
              <p content-type="published/updated">This article was published on December 11, 2020, at NEJM.org.</p>
              <p content-type="data-sharing">A <xref rid="ap4" ref-type="app">data sharing statement</xref> provided by the authors is available with the full text of this article at NEJM.org.</p>
            </notes>
            <app-group>
              <app content-type="protocol" id="ap1">
                <title>Protocol</title>
                <supplementary-material position="float" content-type="local-data">
                  <media xlink:href="NEJMoa2031994_protocol.pdf">
                    <caption>
                      <p>Click here for additional data file.</p>
                    </caption>
                  </media>
                </supplementary-material>
              </app>
              <app content-type="supplementary-appendix" id="ap2">
                <title>Supplementary Appendix</title>
                <supplementary-material position="float" content-type="local-data">
                  <media xlink:href="NEJMoa2031994_appendix.pdf">
                    <caption>
                      <p>Click here for additional data file.</p>
                    </caption>
                  </media>
                </supplementary-material>
              </app>
              <app content-type="disclosures" id="ap3">
                <title>Disclosure Forms</title>
                <supplementary-material position="float" content-type="local-data">
                  <media xlink:href="NEJMoa2031994_disclosures.pdf">
                    <caption>
                      <p>Click here for additional data file.</p>
                    </caption>
                  </media>
                </supplementary-material>
              </app>
              <app content-type="supplementary-appendix" id="ap4">
                <title>Data Sharing Statement</title>
                <supplementary-material position="float" content-type="local-data">
                  <media xlink:href="NEJMoa2031994_data-sharing.pdf">
                    <caption>
                      <p>Click here for additional data file.</p>
                    </caption>
                  </media>
                </supplementary-material>
              </app>
            </app-group>
            <ref-list>
              <title>References</title>
              <ref id="r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><string-name><surname>Beigel</surname><given-names>JH</given-names></string-name>, <string-name><surname>Tomashek</surname><given-names>KM</given-names></string-name>, <string-name><surname>Dodd</surname><given-names>LE</given-names></string-name>, <etal>et al.</etal><article-title>Remdesivir for the treatment of Covid-19 — final report.</article-title><source>N Engl J Med</source><year>2020</year>;<volume>383</volume>:<fpage>1813</fpage>-<lpage>1826</lpage>.<?supplied-pmid 32445440?><pub-id pub-id-type="pmid">32445440</pub-id></mixed-citation>
              </ref>
              <ref id="r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><string-name><surname>Mehta</surname><given-names>P</given-names></string-name>, <string-name><surname>McAuley</surname><given-names>DF</given-names></string-name>, <string-name><surname>Brown</surname><given-names>M</given-names></string-name>, <string-name><surname>Sanchez</surname><given-names>E</given-names></string-name>, <string-name><surname>Tattersall</surname><given-names>RS</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JJ</given-names></string-name>. <article-title>COVID-19: consider cytokine storm syndromes and immunosuppression.</article-title><source>Lancet</source><year>2020</year>;<volume>395</volume>:<fpage>1033</fpage>-<lpage>1034</lpage>.<?supplied-pmid 32192578?><pub-id pub-id-type="pmid">32192578</pub-id></mixed-citation>
              </ref>
              <ref id="r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><string-name><surname>Stebbing</surname><given-names>J</given-names></string-name>, <string-name><surname>Phelan</surname><given-names>A</given-names></string-name>, <string-name><surname>Griffin</surname><given-names>I</given-names></string-name>, <etal>et al.</etal><article-title>COVID-19: combining antiviral and anti-inflammatory treatments.</article-title><source>Lancet Infect Dis</source><year>2020</year>;<volume>20</volume>:<fpage>400</fpage>-<lpage>402</lpage>.<?supplied-pmid 32113509?><pub-id pub-id-type="pmid">32113509</pub-id></mixed-citation>
              </ref>
              <ref id="r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><string-name><surname>Richardson</surname><given-names>P</given-names></string-name>, <string-name><surname>Griffin</surname><given-names>I</given-names></string-name>, <string-name><surname>Tucker</surname><given-names>C</given-names></string-name>, <etal>et al.</etal><article-title>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease.</article-title><source>Lancet</source><year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>e30</fpage>-<lpage>e31</lpage>.<?supplied-pmid 32032529?><pub-id pub-id-type="pmid">32032529</pub-id></mixed-citation>
              </ref>
              <ref id="r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><string-name><surname>Stebbing</surname><given-names>J</given-names></string-name>, <string-name><surname>Krishnan</surname><given-names>V</given-names></string-name>, <string-name><surname>de Bono</surname><given-names>S</given-names></string-name>, <etal>et al.</etal><article-title>Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients.</article-title><source>EMBO Mol Med</source><year>2020</year>;<volume>12</volume>(<issue>8</issue>):<fpage>e12697</fpage>-<lpage>e12697</lpage>.<?supplied-pmid 32473600?><pub-id pub-id-type="pmid">32473600</pub-id></mixed-citation>
              </ref>
              <ref id="r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><string-name><surname>Sims</surname><given-names>JT</given-names></string-name>, <string-name><surname>Krishnan</surname><given-names>V</given-names></string-name>, <string-name><surname>Chang</surname><given-names>C-Y</given-names></string-name>, <etal>et al.</etal><article-title>Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19.</article-title><source>J Allergy Clin Immunol</source><year>2020</year><month>September</month><day>10</day><comment>(Epub ahead of print)</comment>.<?supplied-pmid 32920092?><pub-id pub-id-type="pmid">32920092</pub-id></mixed-citation>
              </ref>
              <ref id="r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><string-name><surname>Cantini</surname><given-names>F</given-names></string-name>, <string-name><surname>Niccoli</surname><given-names>L</given-names></string-name>, <string-name><surname>Matarrese</surname><given-names>D</given-names></string-name>, <string-name><surname>Nicastri</surname><given-names>E</given-names></string-name>, <string-name><surname>Stobbione</surname><given-names>P</given-names></string-name>, <string-name><surname>Goletti</surname><given-names>D</given-names></string-name>. <article-title>Baricitinib therapy in COVID-19: a pilot study on safety and clinical impact.</article-title><source>J Infect</source><year>2020</year>;<volume>81</volume>:<fpage>318</fpage>-<lpage>356</lpage>.<?supplied-pmid 32333918?><pub-id pub-id-type="pmid">32333918</pub-id></mixed-citation>
              </ref>
              <ref id="r8">
                <label>8</label>
                <mixed-citation publication-type="eref"><string-name><surname>Hoang</surname><given-names>TN</given-names></string-name>, <string-name><surname>Pino</surname><given-names>M</given-names></string-name>, <string-name><surname>Boddapati</surname><given-names>AK</given-names></string-name>, <etal>et al.</etal><article-title>Baricitinib treatment resolves lower airway inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques.</article-title><month>September</month><day>16</day>, <year>2020</year> (<uri xlink:href="https://www.biorxiv.org/content/10.1101/2020.09.16.300277v1">https://www.biorxiv.org/content/10.1101/2020.09.16.300277v1</uri>). <comment>preprint</comment>.</mixed-citation>
              </ref>
              <ref id="r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><string-name><surname>Titanji</surname><given-names>BK</given-names></string-name>, <string-name><surname>Farley</surname><given-names>MM</given-names></string-name>, <string-name><surname>Mehta</surname><given-names>A</given-names></string-name>, <etal>et al.</etal><article-title>Use of baricitinib in patients with moderate and severe COVID-19.</article-title><source>Clin Infect Dis</source><year>2020</year><month>June</month><day>29</day><comment>(Epub ahead of print)</comment>.<?supplied-pmid 32597466?><pub-id pub-id-type="pmid">32597466</pub-id></mixed-citation>
              </ref>
              <ref id="r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><string-name><surname>Cantini</surname><given-names>F</given-names></string-name>, <string-name><surname>Niccoli</surname><given-names>L</given-names></string-name>, <string-name><surname>Nannini</surname><given-names>C</given-names></string-name>, <etal>et al.</etal><article-title>Beneficial impact of baricitinib in COVID-19 moderate pneumonia; multicentre study.</article-title><source>J Infect</source><year>2020</year>;<volume>81</volume>:<fpage>647</fpage>-<lpage>679</lpage>.<?supplied-pmid 32592703?><pub-id pub-id-type="pmid">32592703</pub-id></mixed-citation>
              </ref>
              <ref id="r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><string-name><surname>Rodriguez-Garcia</surname><given-names>JL</given-names></string-name>, <string-name><surname>Sanchez-Nievas</surname><given-names>G</given-names></string-name>, <string-name><surname>Arevalo-Serrano</surname><given-names>J</given-names></string-name>, <string-name><surname>Garcia-Gomez</surname><given-names>C</given-names></string-name>, <string-name><surname>Jimenez-Vizuete</surname><given-names>JM</given-names></string-name>, <string-name><surname>Martinez-Alfaro</surname><given-names>E</given-names></string-name>. <article-title>Baricitinib improves respiratory function in patients treated with corticosteroids for SARS-CoV-2 pneumonia: an observational cohort study.</article-title><source>Rheumatology (Oxford)</source><year>2020</year><month>October</month><day>6</day><comment>(Epub ahead of print)</comment>.<?supplied-pmid 33020836?><pub-id pub-id-type="pmid">33020836</pub-id></mixed-citation>
              </ref>
              <ref id="r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><string-name><surname>Kalil</surname><given-names>AC</given-names></string-name>. <article-title>Treating COVID-19 — off-label drug use, compassionate use, and randomized clinical trials during pandemics.</article-title><source>JAMA</source><year>2020</year>;<volume>323</volume>:<fpage>1897</fpage>-<lpage>1898</lpage>.<?supplied-pmid 32208486?><pub-id pub-id-type="pmid">32208486</pub-id></mixed-citation>
              </ref>
              <ref id="r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><string-name><surname>Dodd</surname><given-names>LE</given-names></string-name>, <string-name><surname>Follmann</surname><given-names>D</given-names></string-name>, <string-name><surname>Wang</surname><given-names>J</given-names></string-name>, <etal>et al.</etal><article-title>Endpoints for randomized controlled clinical trials for COVID-19 treatments.</article-title><source>Clin Trials</source><year>2020</year>;<volume>17</volume>:<fpage>472</fpage>-<lpage>482</lpage>.<?supplied-pmid 32674594?><pub-id pub-id-type="pmid">32674594</pub-id></mixed-citation>
              </ref>
              <ref id="r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><string-name><surname>Ko</surname><given-names>JY</given-names></string-name>, <string-name><surname>Danielson</surname><given-names>ML</given-names></string-name>, <string-name><surname>Town</surname><given-names>M</given-names></string-name>, <etal>et al.</etal><article-title>Risk factors for COVID-19-associated hospitalization: COVID-19-Associated Hospitalization Surveillance Network and Behavioral Risk Factor Surveillance System.</article-title><source>Clin Infect Dis</source><year>2020</year><month>September</month><day>18</day><comment>(Epub ahead of print)</comment>.<?supplied-pmid 32945846?><pub-id pub-id-type="pmid">32945846</pub-id></mixed-citation>
              </ref>
              <ref id="r15">
                <label>15</label>
                <mixed-citation publication-type="journal" specific-use="OLF"><collab>The RECOVERY Collaborative Group</collab>. <article-title>Dexamethasone in hospitalized patients with Covid-19 — preliminary report.</article-title><source>N Engl J Med</source>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa2021436</pub-id>.</mixed-citation>
              </ref>
              <ref id="r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><string-name><surname>Yao</surname><given-names>T-C</given-names></string-name>, <string-name><surname>Huang</surname><given-names>Y-W</given-names></string-name>, <string-name><surname>Chang</surname><given-names>S-M</given-names></string-name>, <string-name><surname>Tsai</surname><given-names>S-Y</given-names></string-name>, <string-name><surname>Chen Wu</surname><given-names>A</given-names></string-name>, <string-name><surname>Tsai</surname><given-names>H-J</given-names></string-name>. <article-title>Association between oral corticosteroid bursts and severe adverse events: a nationwide population-based cohort study.</article-title><source>Ann Intern Med</source><year>2020</year>;<volume>173</volume>:<fpage>325</fpage>-<lpage>330</lpage>.<?supplied-pmid 32628532?><pub-id pub-id-type="pmid">32628532</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
          <floats-group>
            <fig position="float" id="f1">
              <label>Figure 1</label>
              <caption>
                <title>Enrollment and Randomization.</title>
                <p>RDV denotes remdesivir.</p>
              </caption>
              <graphic xlink:href="NEJMoa2031994_f1" position="float"/>
            </fig>
            <fig position="float" id="f2">
              <label>Figure 2</label>
              <caption>
                <title>Kaplan–Meier Estimates of Cumulative Recoveries.</title>
                <p>Cumulative recovery estimates are shown in the overall population (Panel A), in patients with a baseline score of 4 on the ordinal scale (not requiring oxygen; Panel B), in those with a baseline score of 5 (requiring oxygen; Panel C), in those with a baseline score of 6 (receiving high-flow oxygen or noninvasive mechanical ventilation; Panel D), and in those with a baseline score of 7 (receiving mechanical ventilation or extracorporeal membrane oxygenation [ECMO]; Panel E). Shaded areas indicate 95% confidence intervals.</p>
              </caption>
              <graphic xlink:href="NEJMoa2031994_f2" position="float"/>
            </fig>
            <fig position="float" id="f3">
              <label>Figure 3</label>
              <caption>
                <title>Time to Recovery According to Subgroup.</title>
                <p>The widths of the confidence intervals have not been adjusted for multiplicity and therefore cannot be used to infer treatment effects. Race and ethnic group were reported by the patients. With respect to “other” race, the categories that were used when data on race were reported included American Indian or Alaska Native and Native Hawaiian or other Pacific Islander.</p>
              </caption>
              <graphic xlink:href="NEJMoa2031994_f3" position="float"/>
            </fig>
            <table-wrap position="float" id="t1">
              <label>Table 1</label>
              <caption>
                <title>Demographic and Clinical Characteristics of the Patients at Baseline.<xref rid="t1fn1" ref-type="table-fn">*</xref></title>
              </caption>
              <alternatives>
                <graphic xlink:href="NEJMoa2031994_t1" position="float"/>
                <table frame="hsides" rules="groups" content-type="tgroup">
                  <colgroup span="1">
                    <col id="t1col1" width="44.12%" span="1"/>
                    <col id="t1col2" width="17.52%" span="1"/>
                    <col id="t1col3" width="18.35%" span="1"/>
                    <col id="t1col4" width="20.02%" span="1"/>
                  </colgroup>
                  <thead content-type="thead sticky">
                    <tr content-type="row head1">
                      <th align="left" valign="bottom" content-type="entry txlx-borders" rowspan="1" colspan="1">Characteristic</th>
                      <th align="center" valign="bottom" content-type="entry txxx-borders" rowspan="1" colspan="1">All Patients<break/>(N=1033)</th>
                      <th align="center" valign="bottom" content-type="entry txxx-borders" rowspan="1" colspan="1">Baricitinib+RDV<break/>(N=515)</th>
                      <th align="center" valign="bottom" content-type="entry txxr-borders" rowspan="1" colspan="1">Placebo+RDV<break/>(N=518)</th>
                    </tr>
                  </thead>
                  <tbody content-type="tbody">
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders hanging03 shading" rowspan="1" colspan="1">Age</td>
                      <td align="center" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="center" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="center" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13" rowspan="1" colspan="1">Mean — yr</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">55.4±15.7</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">55.0±15.4</td>
                      <td align="center" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1">55.8±16.0</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13 shading" rowspan="1" colspan="1">Distribution — no. (%)</td>
                      <td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders hanging23" rowspan="1" colspan="1">&lt;40 yr</td>
                      <td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">173 (16.7)</td>
                      <td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">87 (16.9)</td>
                      <td content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">86 (16.6)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging23 shading" rowspan="1" colspan="1">40–64 yr</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">555 (53.7)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">281 (54.6)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">274 (52.9)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging23" rowspan="1" colspan="1">≥65 yr</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">305 (29.5)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">147 (28.5)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">158 (30.5)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging03 shading" rowspan="1" colspan="1">Sex — no. (%)</td>
                      <td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13" rowspan="1" colspan="1">Female</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">381 (36.9)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">196 (38.1)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">185 (35.7)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13 shading" rowspan="1" colspan="1">Male</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">652 (63.1)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">319 (61.9)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">333 (64.3)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging03" rowspan="1" colspan="1">Race — no. (%)<xref rid="t1fn2" ref-type="table-fn">†</xref></td>
                      <td align="left" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13 shading" rowspan="1" colspan="1">Asian</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">101 (9.8)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">49 (9.5)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">52 (10.0)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13" rowspan="1" colspan="1">Black</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">156 (15.1)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">77 (15.0)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">79 (15.3)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13 shading" rowspan="1" colspan="1">White</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">496 (48.0)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">251 (48.7)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">245 (47.3)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13" rowspan="1" colspan="1">Other or unknown</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">280 (27.1)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">138 (26.8)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">142 (27.4)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging03 shading" rowspan="1" colspan="1">Ethnic group — no. (%)<xref rid="t1fn2" ref-type="table-fn">†</xref></td>
                      <td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13" rowspan="1" colspan="1">Hispanic or Latino</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">531 (51.4)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">263 (51.1)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">268 (51.7)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13 shading" rowspan="1" colspan="1">Not Hispanic or Latino</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">486 (47.0)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">246 (47.8)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">240 (46.3)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13" rowspan="1" colspan="1">Not reported or unknown</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">16 (1.5)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">6 (1.2)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">10 (1.9)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging03 shading" rowspan="1" colspan="1">Body-mass index<xref rid="t1fn3" ref-type="table-fn">‡</xref></td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">32.2±8.3</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">32.2±8.2</td>
                      <td align="center" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1">32.3±8.4</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging03" rowspan="1" colspan="1">Median time (IQR) from symptom onset to randomization — days</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">8 (5–10)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">8 (5–10)</td>
                      <td align="center" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1">8 (5–11)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging03 shading" rowspan="1" colspan="1">Disease severity — no. (%)</td>
                      <td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13" rowspan="1" colspan="1">Moderate</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">706 (68.3)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">358 (69.5)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">348 (67.2)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13 shading" rowspan="1" colspan="1">Severe</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">327 (31.7)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">157 (30.5)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">170 (32.8)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging03" rowspan="1" colspan="1">Coexisting conditions — no./total no. (%)</td>
                      <td align="left" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13 shading" rowspan="1" colspan="1">None</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="/" rowspan="1" colspan="1">155/994 (15.6)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="/" rowspan="1" colspan="1">64/496 (12.9)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="/" rowspan="1" colspan="1">91/498 (18.3)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13" rowspan="1" colspan="1">One</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="/" rowspan="1" colspan="1">270/994 (27.2)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="/" rowspan="1" colspan="1">148/496 (29.8)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="/" rowspan="1" colspan="1">122/498 (24.5)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13 shading" rowspan="1" colspan="1">Two or more</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="/" rowspan="1" colspan="1">569/994 (57.2)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="/" rowspan="1" colspan="1">284/496 (57.3)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="/" rowspan="1" colspan="1">285/498 (57.2)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging03" rowspan="1" colspan="1">Score on ordinal scale — no. (%)</td>
                      <td align="left" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13 shading" rowspan="1" colspan="1">4. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (Covid-19–related or otherwise)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">142 (13.7)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">70 (13.6)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">72 (13.9)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13" rowspan="1" colspan="1">5. Hospitalized, requiring supplemental oxygen</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">564 (54.6)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">288 (55.9)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">276 (53.3)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13 shading" rowspan="1" colspan="1">6. Hospitalized, receiving noninvasive ventilation or high-flow oxygen devices</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">216 (20.9)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">103 (20.0)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">113 (21.8)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13" rowspan="1" colspan="1">7. Hospitalized, receiving invasive mechanical ventilation or ECMO</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">111 (10.7)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">54 (10.5)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">57 (11.0)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging03 shading" rowspan="1" colspan="1">Geographic region — no. (%)</td>
                      <td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13" rowspan="1" colspan="1">Asia</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">67 (6.5)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">33 (6.4)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">34 (6.6)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging13 shading" rowspan="1" colspan="1">Europe</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">13 (1.3)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">6 (1.2)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">7 (1.4)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xblx-borders hanging13" rowspan="1" colspan="1">North America</td>
                      <td valign="top" content-type="entry xbxx-borders" align="char" char="(" rowspan="1" colspan="1">953 (92.3)</td>
                      <td valign="top" content-type="entry xbxx-borders" align="char" char="(" rowspan="1" colspan="1">476 (92.4)</td>
                      <td valign="top" content-type="entry xbxr-borders" align="char" char="(" rowspan="1" colspan="1">477 (92.1)</td>
                    </tr>
                  </tbody>
                </table>
              </alternatives>
              <table-wrap-foot>
                <fn id="t1fn1">
                  <label>*</label>
                  <p>Plus–minus values are means ±SD. Percentages may not total 100 because of rounding. Covid-19 denotes coronavirus disease 2019, ECMO extracorporeal membrane oxygenation, IQR interquartile range, and RDV remdesivir.</p>
                </fn>
                <fn id="t1fn2">
                  <label>†</label>
                  <p>Race and ethnic group were reported by the patients. With respect to “other” race, the categories that were used when data on race were reported included American Indian or Alaska Native and Native Hawaiian or other Pacific Islander.</p>
                </fn>
                <fn id="t1fn3">
                  <label>‡</label>
                  <p>The body-mass index is the weight in kilograms divided by the square of the height in meters.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap position="float" id="t2">
              <label>Table 2</label>
              <caption>
                <title>Outcomes Overall and According to Score on the Ordinal Scale in the Intention-to-Treat Population.<xref rid="t2fn1" ref-type="table-fn">*</xref></title>
              </caption>
              <alternatives>
                <graphic xlink:href="NEJMoa2031994_t2" position="float"/>
                <table frame="hsides" rules="groups" content-type="tgroup">
                  <colgroup span="1">
                    <col id="t2col1" width="25.29%" span="1"/>
                    <col id="t2col2" width="8.01%" span="1"/>
                    <col id="t2col3" width="8.63%" span="1"/>
                    <col id="t2col4" width="7.78%" span="1"/>
                    <col id="t2col5" width="6.70%" span="1"/>
                    <col id="t2col6" width="7.92%" span="1"/>
                    <col id="t2col7" width="6.55%" span="1"/>
                    <col id="t2col8" width="7.99%" span="1"/>
                    <col id="t2col9" width="6.55%" span="1"/>
                    <col id="t2col10" width="7.85%" span="1"/>
                    <col id="t2col11" width="6.70%" span="1"/>
                  </colgroup>
                  <thead content-type="thead sticky">
                    <tr content-type="row head1">
                      <th align="left" valign="bottom" content-type="entry txlx-borders" rowspan="1" colspan="1">Outcome</th>
                      <th align="center" valign="bottom" colspan="2" content-type="entry txxx-borders" rowspan="1">Overall</th>
                      <th align="center" colspan="8" content-type="entry txxr-borders" rowspan="1">Ordinal Score at Baseline</th>
                    </tr>
                    <tr content-type="row head2">
                      <th align="left" valign="bottom" content-type="entry xxlx-borders" rowspan="1" colspan="1"/>
                      <th align="center" valign="bottom" colspan="2" content-type="entry xxxx-borders" rowspan="1"/>
                      <th align="center" valign="bottom" colspan="2" content-type="entry xxxx-borders" rowspan="1">4</th>
                      <th align="center" valign="bottom" colspan="2" content-type="entry xxxx-borders" rowspan="1">5</th>
                      <th align="center" valign="bottom" colspan="2" content-type="entry xxxx-borders" rowspan="1">6</th>
                      <th align="center" valign="bottom" colspan="2" content-type="entry xxxr-borders" rowspan="1">7</th>
                    </tr>
                    <tr content-type="row head2">
                      <th align="left" valign="top" content-type="entry xxlx-borders hanging01" rowspan="1" colspan="1"/>
                      <th align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">Baricitinib<break/>(N=515)</th>
                      <th align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">Placebo<break/>(N=518)</th>
                      <th align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">Baricitinib<break/>(N=70)</th>
                      <th align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">Placebo<break/>(N=72)</th>
                      <th align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">Baricitinib<break/>(N=288)</th>
                      <th align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">Placebo<break/>(N=276)</th>
                      <th align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">Baricitinib<break/>(N=103)</th>
                      <th align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">Placebo<break/>(N=113)</th>
                      <th align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">Baricitinib<break/>(N=54)</th>
                      <th align="center" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1">Placebo<break/>(N=57)</th>
                    </tr>
                  </thead>
                  <tbody content-type="tbody">
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01 shading" rowspan="1" colspan="1">
                        <bold>Recovery</bold>
                      </td>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01" rowspan="1" colspan="1">No. of recoveries</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">433</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">406</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">67</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">69</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">262</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">243</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">82</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">73</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">22</td>
                      <td align="center" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1">21</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01 shading" rowspan="1" colspan="1">Median time to recovery (95% CI) — days</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">7<break/>(6–8)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">8<break/>(7–9)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">5<break/>(4–6)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">4<break/>(4–6)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">5<break/>(5–6)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">6<break/>(5–6)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">10<break/>(9–13)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">18<break/>(13–21)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">NE<break/>(25–NE)</td>
                      <td align="center" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1">NE<break/>(26–NE)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01" rowspan="1" colspan="1">Rate ratio (95% CI)<xref rid="t2fn2" ref-type="table-fn">†</xref></td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxx-borders" rowspan="1">1.16 (1.01–1.32 [P=0.03])</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxx-borders" rowspan="1">0.88 (0.63–1.23)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxx-borders" rowspan="1">1.17 (0.98–1.39)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxx-borders" rowspan="1">1.51 (1.10–2.08)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxr-borders" rowspan="1">1.08 (0.59–1.97)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01 shading" rowspan="1" colspan="1">
                        <bold>Mortality over first 14 days<xref rid="t2fn3" ref-type="table-fn">‡</xref></bold>
                      </td>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01" rowspan="1" colspan="1">Hazard ratio (95% CI) for data through day 14</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxx-borders" rowspan="1">0.54 (0.23–1.28)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxx-borders" rowspan="1">NE</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxx-borders" rowspan="1">0.73 (0.16–3.26)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxx-borders" rowspan="1">0.21 (0.02–1.80)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxr-borders" rowspan="1">0.69 (0.19–2.44)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01 shading" rowspan="1" colspan="1">No. of deaths by day 14</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">8</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">15</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">3</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">4</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">1</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">5</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">4</td>
                      <td align="center" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1">6</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01" rowspan="1" colspan="1">Kaplan–Meier estimate of mortality by day 14 — % (95% CI)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">1.6<break/>(0.8–3.2)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">3.0<break/>(1.8–5.0)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0<break/>(NE–NE)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0<break/>(NE–NE)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">1.1<break/>(0.4–3.4)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">1.5<break/>(0.6–3.9)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">1.0<break/>(0.1–6.7)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">4.6<break/>(2.0–10.8)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">7.6<break/>(2.9–19.1)</td>
                      <td align="center" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1">11.3<break/>(5.3–23.5)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01 shading" rowspan="1" colspan="1">
                        <bold>Mortality over entire trial period<xref rid="t2fn3" ref-type="table-fn">‡</xref></bold>
                      </td>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01" rowspan="1" colspan="1">Hazard ratio (95% CI)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxx-borders" rowspan="1">0.65 (0.39–1.09)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxx-borders" rowspan="1">NE</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxx-borders" rowspan="1">0.40 (0.14–1.14)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxx-borders" rowspan="1">0.55 (0.22–1.38)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xxxr-borders" rowspan="1">1.00 (0.45–2.22)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01 shading" rowspan="1" colspan="1">No. of deaths by day 28</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">24</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">37</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">5</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">12</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">7</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">13</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">12</td>
                      <td align="center" valign="top" content-type="entry xxxr-borders shading" rowspan="1" colspan="1">12</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01" rowspan="1" colspan="1">Kaplan–Meier estimate of mortality by day 28 — % (95% CI)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">5.1<break/>(3.5–7.6)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">7.8<break/>(5.7–10.6)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0<break/>(NE–NE)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0<break/>(NE–NE)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">1.9<break/>(0.8–4.4)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">4.7<break/>(2.7–8.1)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">7.5<break/>(3.6–15.2)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">12.9<break/>(7.7–21.3)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">23.1<break/>(13.8–37.1)</td>
                      <td align="center" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1">22.6<break/>(13.5–36.4)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01 shading" rowspan="1" colspan="1">
                        <bold>Ordinal score at day 15 (±2 days) — no. (%)<xref rid="t2fn4" ref-type="table-fn">§</xref></bold>
                      </td>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01" rowspan="1" colspan="1">1</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">177 (34.4)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">165 (31.9)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">33 (47.1)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">44 (61.1)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">114 (39.6)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">101 (36.6)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">27 (26.2)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">17 (15.0)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">3 (5.6)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">3 (5.3)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01 shading" rowspan="1" colspan="1">2</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">177 (34.4)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">163 (31.5)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">25 (35.7)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">20 (27.8)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">120 (41.7)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">115 (41.7)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">30 (29.1)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">24 (21.2)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (3.7)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">4 (7.0)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01" rowspan="1" colspan="1">3</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">8 (1.6)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">3 (0.6)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">5 (7.1)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">2 (2.8)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">2 (0.7)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">1 (0.4)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">1 (1.9)</td>
                      <td align="center" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1">0</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01 shading" rowspan="1" colspan="1">4</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">31 (6.0)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">18 (3.5)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">7 (10.0)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">6 (8.3)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">14 (4.9)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">7 (2.5)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">7 (6.8)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">3 (2.7)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">3 (5.6)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (3.5)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01" rowspan="1" colspan="1">5</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">43 (8.3)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">50 (9.7)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">18 (6.2)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">27 (9.8)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">15 (14.6)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">20 (17.7)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">10 (18.5)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">3 (5.3)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01 shading" rowspan="1" colspan="1">6</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">20 (3.9)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">19 (3.7)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">9 (3.1)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">1 (0.4)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">7 (6.8)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">16 (14.2)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">4 (7.4)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (3.5)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01" rowspan="1" colspan="1">7</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">48 (9.3)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">83 (16.0)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">0</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">8 (2.8)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">19 (6.9)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">15 (14.6)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">28 (24.8)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">25 (46.3)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">36 (63.2)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging01 shading" rowspan="1" colspan="1">8</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">11 (2.1)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">17 (3.3)</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">0</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">3 (1.0)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">5 (1.8)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (1.9)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">5 (4.4)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">6 (11.1)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">7 (12.3)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xblx-borders hanging01" rowspan="1" colspan="1">Odds ratio (95% CI)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xbxx-borders" rowspan="1">1.3 (1.0–1.6)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xbxx-borders" rowspan="1">0.6 (0.3–1.1)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xbxx-borders" rowspan="1">1.2 (0.9–1.6)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xbxx-borders" rowspan="1">2.2 (1.4–3.6)</td>
                      <td align="center" valign="top" colspan="2" content-type="entry xbxr-borders" rowspan="1">1.7 (0.8–3.4)</td>
                    </tr>
                  </tbody>
                </table>
              </alternatives>
              <table-wrap-foot>
                <fn id="t2fn1">
                  <label>*</label>
                  <p>Patients in both groups received RDV in addition to either baricitinib or placebo. Neither the P value nor any confidence intervals have not been adjusted for multiple comparisons. Percentages may not total 100 because of rounding. NE denotes not possible to estimate.</p>
                </fn>
                <fn id="t2fn2">
                  <label>†</label>
                  <p>Rate ratios for recovery and hazard ratios were calculated from the stratified Cox model. The P value for the primary outcome was calculated with the stratified log-rank test (overall model stratified according to actual disease severity). Rate ratios for recovery greater than 1 indicate a benefit with baricitinib plus RDV; hazard ratios less than 1 indicate a benefit with baricitinib plus RDV.</p>
                </fn>
                <fn id="t2fn3">
                  <label>‡</label>
                  <p>Mortality over the first 14 days includes data from all patients who were still alive through 14 days after enrollment, with data censored on day 14, as if 14 days was the maximum follow-up time. Mortality over the entire trial period uses the totality of the trial data and censors data from patients who completed follow-up alive at 28 days after enrollment.</p>
                </fn>
                <fn id="t2fn4">
                  <label>§</label>
                  <p>The ordinal score at day 15 (±2-day visit window) is the patient’s worst score on the ordinal scale during the previous day. Scores on the ordinal scale are as follows: 1, not hospitalized, no limitations of activities; 2, not hospitalized, limitation of activities, home oxygen requirement, or both; 3, hospitalized, not requiring supplemental oxygen and no longer requiring ongoing medical care (used if hospitalization was extended for infection-control reasons); 4, hospitalized, not requiring supplemental oxygen but requiring ongoing medical care (Covid-19–related or other medical conditions); 5, hospitalized, requiring any supplemental oxygen; 6, hospitalized, receiving noninvasive ventilation or use of high-flow oxygen devices; 7, hospitalized, receiving invasive mechanical ventilation or ECMO; and 8, death. Five deaths (three in patients receiving baricitinib plus RDV and two in patients receiving placebo plus RDV) occurred within the day 15 visit window but after 14 days — these deaths are included in the outcome of the ordinal score at day 15 but not in the outcome of mortality over the first 14 days. Odds ratios were calculated with the use of a proportional odds model (overall model adjusted for actual disease severity). Odds ratios greater than 1 indicate a benefit with baricitinib plus RDV.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <table-wrap position="float" id="t3">
              <label>Table 3</label>
              <caption>
                <title>Additional Secondary Outcomes.</title>
              </caption>
              <alternatives>
                <graphic xlink:href="NEJMoa2031994_t3" position="float"/>
                <table frame="hsides" rules="groups" content-type="tgroup">
                  <colgroup span="1">
                    <col id="t3col2" width="46.52%" span="1"/>
                    <col id="t3col3" width="14.74%" span="1"/>
                    <col id="t3col4" width="14.80%" span="1"/>
                    <col id="t3col5" width="14.67%" span="1"/>
                  </colgroup>
                  <thead content-type="thead sticky">
                    <tr content-type="row head1">
                      <th align="left" content-type="entry txlx-borders" rowspan="1" colspan="1">Outcome</th>
                      <th align="center" valign="bottom" content-type="entry txxx-borders" rowspan="1" colspan="1">Baricitinib+RDV</th>
                      <th align="center" valign="bottom" content-type="entry txxx-borders" rowspan="1" colspan="1">Placebo+RDV</th>
                      <th align="center" valign="bottom" content-type="entry txxr-borders" rowspan="1" colspan="1">Rate Ratio (95% CI)</th>
                    </tr>
                  </thead>
                  <tbody content-type="tbody">
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders shading" rowspan="1" colspan="1">
                        <bold>Median time to event (95% CI) — days</bold>
                      </td>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders" rowspan="1" colspan="1">Improvement by one category on ordinal scale</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">6.0 (5.0 to 7.0)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">8.0 (7.0 to 9.0)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">1.21 (1.06 to 1.39)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders shading" rowspan="1" colspan="1">Improvement by two categories on ordinal scale</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">12.0 (12.0 to 13.0)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">13.0 (NE)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">1.20 (1.05 to 1.38)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders" rowspan="1" colspan="1">Discharge or National Early Warning Score ≤2 for 24 hr<xref rid="t3fn1" ref-type="table-fn">*</xref></td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">6.0 (6.0 to 7.0)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">7.0 (6.0 to 9.0)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">1.24 (1.07 to 1.44)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging02 shading" rowspan="1" colspan="1">Death or progression to noninvasive or invasive mechanical ventilation</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">NE</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">NE</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">0.77 (0.60 to 0.98)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders" rowspan="1" colspan="1">Death or progression to invasive mechanical ventilation</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">NE</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">NE</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">0.69 (0.50 to 0.95)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders shading" rowspan="1" colspan="1">New use of oxygen</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">NE</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">NE (3.0 to NE)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">0.53 (0.29 to 0.98)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders" rowspan="1" colspan="1">New use of invasive mechanical ventilation or ECMO</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">NE</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1">NE</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">0.64 (0.44 to 0.93)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders shading" rowspan="1" colspan="1">Use of noninvasive ventilation or high-flow oxygen</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">NE</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders shading" rowspan="1" colspan="1">NE</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">0.82 (0.60 to 1.13)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="center" content-type="entry xxxr-borders" rowspan="1" colspan="1">
                        <bold>Difference (95% CI)</bold>
                      </td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders shading" rowspan="1" colspan="1">
                        <bold>Hospitalization</bold>
                      </td>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="center" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders" rowspan="1" colspan="1">Median duration of initial hospitalization (IQR) — days</td>
                      <td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1"/>
                      <td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1"/>
                      <td content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">With imputation of data for those who died<xref rid="t3fn2" ref-type="table-fn">†</xref></td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">8 (5 to 15)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">8 (5 to 20)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">0.0 (−1.1 to 1.1)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Among those who did not die</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">8 (5 to 13)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">8 (5 to 15)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">0.0 (−1.0 to 1.0)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders shading" rowspan="1" colspan="1">Patients rehospitalized — % (95% CI)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">3 (2 to 5)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">2 (1 to 4)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">1.0 (−1.1 to 3.1)<xref rid="t3fn3" ref-type="table-fn">‡</xref></td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders" rowspan="1" colspan="1">
                        <bold>Oxygen</bold>
                      </td>
                      <td align="left" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxr-borders" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders shading" rowspan="1" colspan="1">Median days receiving oxygen if receiving oxygen at baseline (IQR)</td>
                      <td content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1"/>
                      <td content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1"/>
                      <td content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">With imputation of data for those who died<xref rid="t3fn2" ref-type="table-fn">†</xref></td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">10 (4 to 27)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">12 (4 to 28)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">−2.0 (−5.2 to 1.2)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Among those who did not die</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">9 (4 to 23)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">10 (4 to 28)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">−1.0 (−3.5 to 1.5)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders" rowspan="1" colspan="1">New use of oxygen during trial</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">No. of patients/total no.</td>
                      <td content-type="entry xxxx-borders shading" align="char" char="/" rowspan="1" colspan="1">16/70</td>
                      <td content-type="entry xxxx-borders shading" align="char" char="/" rowspan="1" colspan="1">29/72</td>
                      <td align="center" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Percent of patients (95% CI)</td>
                      <td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">23 (15 to 34)</td>
                      <td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">40 (30 to 52)</td>
                      <td content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">−17.4 (−31.6 to −2.1)<xref rid="t3fn3" ref-type="table-fn">‡</xref></td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Median days receiving oxygen (IQR)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">3 (2 to 4)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">3 (2 to 6)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">0.0 (−2.2 to 2.2)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders" rowspan="1" colspan="1">
                        <bold>Noninvasive ventilation or high-flow oxygen</bold>
                      </td>
                      <td align="left" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxr-borders" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders hanging02 shading" rowspan="1" colspan="1">Median days of noninvasive ventilation or high-flow oxygen use during trial if receiving these interventions at baseline (IQR)</td>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">With imputation of data for those who died<xref rid="t3fn2" ref-type="table-fn">†</xref></td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">4 (3 to 9)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">5 (2 to 12)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">−1.0 (−2.9 to 0.9)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Among those who did not die</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">4 (3 to 6)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">4 (2 to 9)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">0.0 (−1.7 to 1.7)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging02" rowspan="1" colspan="1">New use of noninvasive ventilation or high-flow oxygen during trial</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">No. of patients/total no.</td>
                      <td content-type="entry xxxx-borders shading" align="char" char="/" rowspan="1" colspan="1">70/358</td>
                      <td content-type="entry xxxx-borders shading" align="char" char="/" rowspan="1" colspan="1">82/348</td>
                      <td align="center" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Percent of patients (95% CI)</td>
                      <td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">20 (16 to 24)</td>
                      <td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">24 (19 to 28)</td>
                      <td content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">−4.0 (−10.1 to 2.1)<xref rid="t3fn3" ref-type="table-fn">‡</xref></td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Median days of use during trial (IQR)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">6 (3 to 13)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">4 (2 to 11)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">2.0 (−0.4 to 4.4)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders" rowspan="1" colspan="1">
                        <bold>Mechanical ventilation or ECMO</bold>
                      </td>
                      <td align="left" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="left" content-type="entry xxxr-borders" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders hanging02 shading" rowspan="1" colspan="1">Median days of mechanical ventilation or ECMO during trial if receiving these interventions at baseline (IQR)</td>
                      <td align="center" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="center" content-type="entry xxxx-borders shading" rowspan="1" colspan="1"/>
                      <td align="center" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">With imputation of data for those who died<xref rid="t3fn2" ref-type="table-fn">†</xref></td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">20 (9 to 28)</td>
                      <td valign="top" content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">25 (11 to 28)</td>
                      <td valign="top" content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">−5.0 (−12.9 to 2.9)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">Among those who did not die</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">13 (7 to 24)</td>
                      <td valign="top" content-type="entry xxxx-borders shading" align="char" char="(" rowspan="1" colspan="1">16 (6 to 28)</td>
                      <td valign="top" content-type="entry xxxr-borders shading" align="char" char="(" rowspan="1" colspan="1">−2.0 (−11.4 to 7.4)</td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xxlx-borders" rowspan="1" colspan="1">New use of mechanical ventilation or ECMO during trial</td>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" content-type="entry xxxx-borders" rowspan="1" colspan="1"/>
                      <td align="center" valign="top" content-type="entry xxxr-borders" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders hanging12 shading" rowspan="1" colspan="1">No. of patients/total no.</td>
                      <td content-type="entry xxxx-borders shading" align="char" char="/" rowspan="1" colspan="1">46/461</td>
                      <td content-type="entry xxxx-borders shading" align="char" char="/" rowspan="1" colspan="1">70/461</td>
                      <td align="center" content-type="entry xxxr-borders shading" rowspan="1" colspan="1"/>
                    </tr>
                    <tr content-type="row">
                      <td align="left" content-type="entry xxlx-borders hanging12" rowspan="1" colspan="1">Percent of patients (95% CI)</td>
                      <td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">10 (8 to 13)</td>
                      <td content-type="entry xxxx-borders" align="char" char="(" rowspan="1" colspan="1">15 (12 to 19)</td>
                      <td content-type="entry xxxr-borders" align="char" char="(" rowspan="1" colspan="1">−5.2 (−9.5 to −0.9)<xref rid="t3fn3" ref-type="table-fn">‡</xref></td>
                    </tr>
                    <tr content-type="row">
                      <td align="left" valign="top" content-type="entry xblx-borders hanging12 shading" rowspan="1" colspan="1">Median days of use during trial<xref rid="t3fn4" ref-type="table-fn">§</xref></td>
                      <td valign="top" content-type="entry xbxx-borders shading" align="char" char="(" rowspan="1" colspan="1">16 (7 to 28)</td>
                      <td valign="top" content-type="entry xbxx-borders shading" align="char" char="(" rowspan="1" colspan="1">27 (12 to 28)</td>
                      <td valign="top" content-type="entry xbxr-borders shading" align="char" char="(" rowspan="1" colspan="1">−11.0 (−18.3 to −3.7)</td>
                    </tr>
                  </tbody>
                </table>
              </alternatives>
              <table-wrap-foot>
                <fn id="t3fn1">
                  <label>*</label>
                  <p>The National Early Warning Score includes six physiological measures; total scores range from 0 to 20, with higher scores indicating greater clinical risk. Only patients with a score of more than 2 at baseline were included in this analysis.</p>
                </fn>
                <fn id="t3fn2">
                  <label>†</label>
                  <p>The value for patients who died was imputed as 28 days.</p>
                </fn>
                <fn id="t3fn3">
                  <label>‡</label>
                  <p>Differences between percentages are given in percentage points.</p>
                </fn>
                <fn id="t3fn4">
                  <label>§</label>
                  <p>This analysis includes imputation of data for patients who died with no observed new use. A total of 12 patients died without progression to ECMO. All the patients who died had other oxygen use.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </floats-group>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
